Guardant Health, INC Form 4 insider transactions

Guardant Health's Chief Technology Officer, Darya Chudova, reported the pre-planned sale of 5,451 shares of common stock for approximately $104.04 per share.

Guardant Health's CFO, Michael Brian Bell, reported the vesting of restricted stock units and subsequent tax withholding on December 15, 2025, under a pre-arranged plan.

Guardant Health Co-CEO AmirAli Talasaz reported sales of 100,000 common shares and transfers to trusts under a 10b5-1 plan.

Guardant Health's Chief Information Officer, Kumud Kalia, sold 2,000 shares of common stock for approximately $104.60 per share under a Rule 10b5-1 plan.

Guardant Health Director Manuel Hidalgo Medina exercised stock options and subsequently sold a portion of the acquired common stock.

Guardant Health's Chief Technology Officer, Darya Chudova, reported the sale of over 22,000 shares of common stock and a transfer of shares to a family trust.

Guardant Health's Chief Commercial Officer, Chris Freeman, sold 31,252 shares of common stock for over $3.2 million on December 5, 2025, under a pre-arranged trading plan.

Guardant Health's Chief Financial Officer, Michael Brian Bell, exercised stock options and subsequently sold a significant number of common shares.

Guardant Health Director Ian T. Clark exercised stock options and subsequently sold a portion of his indirectly held common stock on December 5, 2025, under a Rule 10b5-1 plan.

Guardant Health's Chief People Officer, Terilyn J. Monroe, exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 plan.

Guardant Health Director Steve Krognes converted 155 Restricted Stock Units into common stock on November 30, 2025, increasing his direct common stock holdings.

Guardant Health Director Roberto Mignone acquired 264 shares of common stock through the vesting of restricted stock units.

Guardant Health Director Tariq Musa sold 116 shares of common stock for $96.25 per share under a pre-arranged Rule 10b5-1 plan.

Guardant Health Director Manuel Hidalgo Medina reported the vesting and conversion of 232 restricted stock units into common stock.

Guardant Health Director Tariq Musa reported the vesting of 250 restricted stock units into common stock, increasing his direct ownership.

Guardant Health Director Manuel Hidalgo Medina exercised stock options and subsequently sold 1,500 shares of common stock on November 7, 2025.

Guardant Health's Chief Legal Officer, John G. Saia, reported a planned future sale of 8,996 shares of common stock at $96.25 per share under a Rule 10b5-1 plan.

Guardant Health Director Steve Krognes converted 154 Restricted Stock Units into common stock on October 31, 2025, as part of a pre-scheduled vesting.

Guardant Health Director Roberto Mignone acquired 3,167 shares of common stock through the vesting of restricted stock units.

Guardant Health Director Manuel Hidalgo Medina acquired 232 shares of common stock through the vesting of Restricted Stock Units on October 17, 2025.

Guardant Health Director Tariq Musa sold 116 shares of common stock for $66.95 per share on October 17, 2025, under a pre-arranged Rule 10b5-1 plan.

Guardant Health Director Myrtle S. Potter sold 26 shares of common stock for $66.95 per share under a pre-arranged Rule 10b5-1 plan.

Guardant Health Director Musa Tariq acquired 250 shares of common stock through the vesting of restricted stock units.

Myrtle S. Potter, a Director at Guardant Health, Inc., reported the vesting of 69 shares of common stock.

Guardant Health's Chief Legal Officer, John G. Saia, increased his direct beneficial ownership of common stock to 52,168 shares following the vesting of restricted stock units and subsequent tax-related sales.

Guardant Health's Chief People Officer, Terilyn J. Monroe, reported the vesting of restricted stock units and subsequent tax-related share withholding.

Guardant Health's Chief Information Officer, Kumud Kalia, reported the vesting of restricted stock units and the sale of shares to cover tax obligations.

Guardant Health's Chief Commercial Officer, Chris Freeman, reported routine acquisitions of common stock through restricted stock unit vesting and subsequent tax-related dispositions.

Guardant Health's Chief Medical Officer, Craig Eagle, reported the vesting of restricted stock units and a corresponding disposition of shares for tax obligations.

Guardant Health's Chief Technology Officer, Darya Chudova, reported the vesting of restricted stock units and subsequent share disposition for tax obligations on October 1, 2025.